Gadoxetate Disodium
This liver-specific gadolinium-based MRI contrast agent is taken up by functioning liver hepatocytes and excreted into bile, providing both vascular and hepatocyte-specific imaging phases. It is particularly useful for detecting and characterizing liver lesions, including small metastases and hepatocellular carcinoma.
Berat Molekul
725,7000 g/mol
TPSA
220,00 Ų
Area Terapeutik
Mekanisme Kerja
Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.
Struktur 2D
Cite this structure
Embed this structure
SMILES
CCOC1=CC=C(C=C1)CC(CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].[Na+].[Na+].[Gd+3]
InChI
InChI=1S/C23H33N3O11.Gd.2Na/c1-2-37-18-5-3-16(4-6-18)9-17(26(14-22(33)34)15-23(35)36)10-24(11-19(27)28)7-8-25(12-20(29)30)13-21(31)32;;;/h3-6,17H,2,7-15H2,1H3,(H,27,28)(H,29,30)(H,31,32)(H,33,34)(H,35,36);;;/q;+3;2*+1/p-5
Molecular Formula
C23H28GdN3Na2O11
HBD / HBA
- / 14
Ikatan yang Dapat Dirotasi
4
Atom Berat
40
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
This liver-specific gadolinium-based MRI contrast agent is taken up by functioning liver hepatocytes and excreted into bile, providing both vascular and hepatocyte-specific imaging phases. It is particularly useful for detecting and characterizing liver lesions, including small metastases and hepatocellular carcinoma.
Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.
Yes, Gadoxetate Disodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2103740. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 91754427. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="gadoxetate-disodium"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/gadoxetate-disodium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/gadoxetate-disodium/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/gadoxetate-disodium/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="gadoxetate-disodium"></drugfyi-drug>